FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316079050> ?p ?o ?g. }

• W4316079050 endingPage "e2154" @default.
• W4316079050 startingPage "e2154" @default.
• W4316079050 abstract "Introduction: Primary duodenal neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy with very poor prognosis. There is no established treatment due to its rarity. Treatment regimens used for small cell lung cancer (SCLC) are used to treat neuroendocrine carcinoma, due to its clinical and histopathological similarities. Therapeutic strategies are poorly understood and not well defined. There is no standardization of therapy even for limited disease and usually multimodal treatment approach is used. Etoposide based treatment regimens have been used mostly in advanced stages. We herein report a case of an aggressive primary duodenal neuroendocrine tumor with excellent response to oxaliplatin-based chemotherapy regimen. Case Description/Methods: We describe a case of a 72-year-old caucasian male who presented to emergency room with abdominal bloating and constipation. He was found to have peritoneal carcinomatosis and marked hydronephrosis in computed tomography (CT) of the chest/abdomen/pelvis. He was further evaluated by urology, oncology, and gastroenterology team. He had paracentesis with removal of 4 L of ascitic fluid. He underwent esophagogastroduodenoscopy, endoscopic ultrasound, and a colonoscopy for further assessment. He was found to have a large mass in the duodenum which upon biopsy was consistent with grade 4 poorly differentiated neuroendocrine carcinoma. Positron emission tomography dotadate scan, peritoneal biopsy and peritoneal fluid cytology further confirmed metastatic neuroendocrine carcinoma. His tumor markers showed elevated Ca 19-9 and chromogranin levels at presentation. Due to his poor performance status and concerns for intolerability to etoposide, he was started on FOLFOX chemotherapy. He completed 12 cycles of chemotherapy with near complete resolution of his disease as evidence by his positron emission tomography dotadate scan and improvements in his tumor markers. Due to excellent response and disease remission, he is currently on xeloda with omission of oxaliplatin. Discussion: Primary duodenal neuroendocrine carcinoma is a relatively rare malignancy with reported incidence of 0.4-2% among all duodenal malignancies. The prognosis is dismal due to presentation as advanced stage at diagnosis. Oxaliplatin based regiments have been shown to have promising anti-tumor activity in gastrointestinal neuroendocrine cancers, however the available data in duodenal gastrointestinal neuroendocrine cancers are very limited." @default.
• W4316079050 created "2023-01-14" @default.
• W4316079050 creator A5027507982 @default.
• W4316079050 creator A5028292483 @default.
• W4316079050 creator A5033140961 @default.
• W4316079050 creator A5060070323 @default.
• W4316079050 creator A5071531064 @default.
• W4316079050 creator A5080618522 @default.
• W4316079050 date "2022-10-01" @default.
• W4316079050 modified "2023-10-02" @default.
• W4316079050 title "S3408 Excellent Treatment Response of an Aggressive Primary Duodenal Neuroendocrine Carcinoma to Oxaliplatin-Based Chemotherapy" @default.
• W4316079050 doi "https://doi.org/10.14309/01.ajg.0000870272.67285.31" @default.
• W4316079050 hasPublicationYear "2022" @default.
• W4316079050 type Work @default.
• W4316079050 citedByCount "0" @default.
• W4316079050 crossrefType "journal-article" @default.
• W4316079050 hasAuthorship W4316079050A5027507982 @default.
• W4316079050 hasAuthorship W4316079050A5028292483 @default.
• W4316079050 hasAuthorship W4316079050A5033140961 @default.
• W4316079050 hasAuthorship W4316079050A5060070323 @default.
• W4316079050 hasAuthorship W4316079050A5071531064 @default.
• W4316079050 hasAuthorship W4316079050A5080618522 @default.
• W4316079050 hasBestOaLocation W43160790501 @default.
• W4316079050 hasConcept C121608353 @default.
• W4316079050 hasConcept C126322002 @default.
• W4316079050 hasConcept C126838900 @default.
• W4316079050 hasConcept C143998085 @default.
• W4316079050 hasConcept C2776694085 @default.
• W4316079050 hasConcept C2778119113 @default.
• W4316079050 hasConcept C2779292878 @default.
• W4316079050 hasConcept C2780962732 @default.
• W4316079050 hasConcept C526805850 @default.
• W4316079050 hasConcept C71924100 @default.
• W4316079050 hasConcept C90924648 @default.
• W4316079050 hasConceptScore W4316079050C121608353 @default.
• W4316079050 hasConceptScore W4316079050C126322002 @default.
• W4316079050 hasConceptScore W4316079050C126838900 @default.
• W4316079050 hasConceptScore W4316079050C143998085 @default.
• W4316079050 hasConceptScore W4316079050C2776694085 @default.
• W4316079050 hasConceptScore W4316079050C2778119113 @default.
• W4316079050 hasConceptScore W4316079050C2779292878 @default.
• W4316079050 hasConceptScore W4316079050C2780962732 @default.
• W4316079050 hasConceptScore W4316079050C526805850 @default.
• W4316079050 hasConceptScore W4316079050C71924100 @default.
• W4316079050 hasConceptScore W4316079050C90924648 @default.
• W4316079050 hasIssue "10S" @default.
• W4316079050 hasLocation W43160790501 @default.
• W4316079050 hasLocation W43160790502 @default.
• W4316079050 hasOpenAccess W4316079050 @default.
• W4316079050 hasPrimaryLocation W43160790501 @default.
• W4316079050 hasRelatedWork W2037724349 @default.
• W4316079050 hasRelatedWork W2061955988 @default.
• W4316079050 hasRelatedWork W2084101102 @default.
• W4316079050 hasRelatedWork W2160763249 @default.
• W4316079050 hasRelatedWork W2417717847 @default.
• W4316079050 hasRelatedWork W2419189404 @default.
• W4316079050 hasRelatedWork W2465617904 @default.
• W4316079050 hasRelatedWork W2468136680 @default.
• W4316079050 hasRelatedWork W2600735778 @default.
• W4316079050 hasRelatedWork W2491155482 @default.
• W4316079050 hasVolume "117" @default.
• W4316079050 isParatext "false" @default.
• W4316079050 isRetracted "false" @default.
• W4316079050 workType "article" @default.